|
||||||||||||||||||||||||||||||||||||
| [
Contents
] [ INDEX ]
|
||||||||||||||||||||||||||||||||||||
| UDK 615.38.06 |
ISSN 035-2899, 39(2014) br.1 p.25-30 |
|||||||||||||||||||||||||||||||||||
|
Original paper Establishment of haemovigilance system in Serbia (Uspostavljanje sistema hemovigilance u Srbiji)
Marija Romić |
||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||
| Download in pdf format | Summary: Introduction/Aim: Haemovigilance presents a series of organized surveillance procedures, in relation to serious adverse events or serious adverse reactions in donors or recipients of blood and blood products, as well as epidemiological surveillance. Serious adverse reactions if they occur in the application of chemoproducts represent a significant clinical problem. They affect the length of the recovery of recipients in a health institution and/or the course of the disease. The aim of this study was to determine how the application haemovigilance system influenced the increasing vigilance of employees in applying chemoproducts, which chemoproducts caused most reactions and which reactions were the most frequent ones. Methods: The recommendations of the Guidelines entitled "The procedure of application of blood components and transfusion reactions: a national guide" were used to establish a haemovigilance system. Communication was done by direct contact: a letter to the health institution introducing the way of keeping records through forms that were compatible with the integrated management systems (IMS). All registered serious adverse reactions in the period 2008-2010 that had occurred in the 47 operational transfusion departments in Serbia were covered. Results: In Serbia during the period 2008-2010, 436 serious adverse events were detected, and in comparison with the number of blood donations made the incidence of 1/1699. The number of detected reaction was three times higher in the period 2008-2010, indicating higher vigilance in monitoring the reactions in the recipients of chemoproducts. The largest number of adverse events referred to concentrated erythrocytes. Conclusion: The survey, conducted in the period 2008-2010 showed that of the total population 3.35% had given blood, which entailed tracking of adverse effects that could occur when giving blood or blood products. The Act on Transfusion states basic definitions including those relating to haemovigilance. Europe has adopted directives defining the level of integration with the transfusion reaction and severity of transfusion reactions. Archiving of samples, as well as parameters for checking traceability, is compulsory according to the Act, which enhances the possibility of confirmation of suspicious results. Key words: haemovigilance, serious adverse reactions, traceability, probability, archiving samples Napomena: kompletan tekst rada na srpskom jeziku Note: full text in Serbian |
|||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||
|
Corresponding Address: Marija Romić Institut za transfuziju krvi Srbije, Svetog Save 39, 11000 Beograd; Srbija; E-mail: m.romic@nbti.org.rs |
Paper received: 4.3.2014 Paper accepted: 9.4.2014 Paper Internet issues: 20.6.2014 |
|||||||||||||||||||||||||||||||||||
| [
Contents
] [ INDEX ]
|
||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||
